Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Animal models of cancer are an immense resource for cancer medicine, but only now are we realising their full potential. What new approaches are needed to derive the maximum value for cancer patients from mouse models of cancer?
Breast cancer is not a single disease, but is instead a collection of diseases that have distinct histopathological features, genetic and genomic variability, and diverse prognostic outcomes. What is the most powerful way to investigate this heterogeneous disease?
The myeloproliferative disorders (MPD) polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors, and most patients with these diseases acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). What are the implications of these findings for MPD?
Accumulating evidence indicates that the active metabolite of vitamin D, 1α,25(OH)2D3, or vitamin D analogues might have potential as anticancer agents because their administration has antiproliferative effects, can activate apoptotic pathways and inhibit angiogenesis. What are the possibilities for 1α,25(OH)2D3and vitamin D analogues as preventative and therapeutic anticancer agents?
Advances in antibody engineering make it possible to produce various recombinant proteins that exploit the specificity of the antibody- combining site to manipulate tumour-related signalling, and to stimulate anti-tumour immune responses. but can we improve antibodies further to fully engage the tumour immune response?
This Perspective discusses the feasibility of identifying oncoantigens (proteins required for tumour progression) using mouse models and human mRNA profiling data. Will such oncoantigens make good cancer vaccine targets?
Oestrogen receptor-a (ERa)-regulated transcription in breast cancer cells involves protein co-factors that contribute to the regulation of chromatin structure. How do these relate with ER activity and potentially with the activity of breast cancer drugs, including tamoxifen?
